Alpha memo: glutathione inflammation combined-protocol attribution boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Replace the source bundle with studies that actually isolate a single component (glycine alone OR NAC alone) versus the GlyNAC combination on the relevant endpoints, so that an attribution boundary can be empirically supported.
2. Alternatively, reframe the memo to honestly describe what the two receipts do show (e.g., pilot-to-extension/follow-up signal, or broader pilot evidence in aging) and drop the unsupported attribution-asymmetry claim.
3. Clarify the actual relationship between the 2021 pilot and the 2024 abstract (likely same cohort, extended follow-up) rather than treating them as independent contrasting evidence.
4. Tighten the research question to match what the receipts can answer; 'does combined protocol transfer to component-attributed endpoints' cannot be answered by two combined-protocol studies.

Major issues

• The two receipts describe essentially the same intervention (GlyNAC supplementation in older adults) and the same overall finding (improvements in glutathione, oxidative stress, mitochondrial function, inflammation, cognition, etc.). The claimed 'attribution boundary' or 'attribution asymmetry' is not supported by the receipts themselves — both are combined-protocol GlyNAC studies, not component-vs-combined comparisons.
• The research question asks whether combined-protocol signals transfer to 'component-attributed endpoint endpoints in human,' but neither receipt isolates a single component; there is no component-only arm in either source. The central analytical claim (attribution asymmetry, component vs. combined) is not grounded in the cited evidence.
• The title promises a 'combined-protocol attribution boundary' as a novel research signal, but the source bundle cannot adjudicate attribution because both receipts test the same combined GlyNAC protocol. The memo fabricates a contrast that the receipts do not provide.
• The synthesis conflates two publications that appear to be from the same research group and overlapping cohorts (the 2024 Gerontological Society abstract is consistent with a 36-week follow-up/extension of the 2021 pilot trial). Treating these as a falsifiable contrast pair is unsupported.

Minor issues

• Phrasing is highly compressed and template-driven, producing awkward constructions like 'endpoint endpoints in human' and 'Receipt 1 axes: adults, human, disease, alzheimer, resistance, function, tolerance.'
• The excerpt from Receipt 1 references Alzheimer's disease while Receipt 2 does not, but this population/design difference is not developed as the actual contrast — the memo invents an attribution-boundary framing instead.
• Receipt-role check and boundary-scope sections use formulaic boilerplate ('disease model/population health, modality, endpoint class, dose, duration, single-component attribution') that does not map to specific differences between the two receipts.

Reviewer note

The memo claims a novel 'combined-protocol attribution boundary' signal, but both cited receipts test the same GlyNAC combination in older adults; neither isolates a single component. The central claim of attribution asymmetry is not grounded in the source bundle. The two sources appear to be overlapping outputs from the same research group (2021 pilot trial and a 2024 abstract consistent with extended follow-up), not an independent falsifier pair. The research question asks about component vs. combined attribution, which cannot be answered by these receipts. Recommend reject: the core analytical claim is materially unsupported and would require a scope reset with appropriate component-only source evidence.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis